塞来昔布对比酮咯酸用于机器人子宫切除术后疼痛管理:一项开放标签随机对照试验
本研究将机器人子宫切除患者随机分为围手术期口服塞来昔布组与术后静脉酮咯酸组,所有患者均接受统一多模式镇痛方案。结果显示两组住院期间疼痛评分无差异,但塞来昔布组处方阿片类药物使用量更少且停用口服阿片类药物更早。
要点
- 机器人子宫切除术后,塞来昔布与酮咯酸在住院疼痛评分上无差异。
- 塞来昔布组处方阿片类药物使用量少于酮咯酸组。
- 塞来昔布组停用口服阿片类药物的时间早于酮咯酸组。
核心结论
- 机器人子宫切除术后多模式镇痛中,塞来昔布与酮咯酸两组住院疼痛评分无差异。
- 术后规律服用塞来昔布7天的患者处方麻醉药品使用量更少。
研究设计与样本
- 开放标签随机对照试验,192例患者评估资格,170例随机分组。
- 开腹子宫切除因入组不佳提前终止(n=32),最终分析138例机器人子宫切除患者。
- 干预组术前口服塞来昔布并持续总共7天,对照组术后立即静脉给予规律酮咯酸。
- 所有患者均接受包含规律对乙酰氨基酚、加巴喷丁及必要时阿片类药物的统一多模式镇痛方案。
主要发现
- 住院疼痛评分两组无差异(2.7 ± 1.9 对比 2.4 ± 1.6,p = 0.21)。
- 平均住院时长两组相似(11.6 ± 8.1 小时 对比 11.9 ± 7.6 小时,p = 0.41)。
- 塞来昔布组处方阿片类药物使用量少于酮咯酸组(6.0 ± 3.6 对比 8.1 ± 4.0,p = 0.001)。
- 塞来昔布组停用口服阿片类药物时间早于酮咯酸组(3.8 ± 2.6 天 对比 5.7 ± 2.8 天,p < 0.001)。
- 住院阿片类药物使用、止吐药使用、围手术期并发症及恢复日常活动天数两组无差异。
局限性
- 开腹子宫切除患者入组因入组不佳提前终止(n=32)。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Compare postoperative pain scores following hysterectomy in patients receiving perioperative celecoxib versus postoperative ketorolac as part of a multimodal pain regimen. METHODS: Patients undergoing hysterectomy were randomized to receive scheduled intravenous ketorolac in the immediate postoperative period or oral celecoxib prior to surgery and continued for a total seven days. All patients received a common multimodal pain protocol consisting of scheduled acetaminophen, gabapentin, and opioids as needed. Inpatient pain scores and postoperative opioid use were analyzed. A questionnaire regarding outpatient opioid use and return to normal activities of daily living (ADLs) was returned two weeks postoperatively. RESULTS: 192 patients were assessed for eligibility and 170 patients were randomized. Enrollment of patients undergoing open hysterectomy was closed prematurely for poor accruement (n = 32). 138 patients undergoing robotic hysterectomy were included were analyzed. There were no differences for inpatient pain scores (2.7 ± 1.9 v. 2.4 ± 1.6, p = 0.21). Average length of stay was similar between the two arms (11.6 ± 8.1 h v. 11.9 ± 7.6 h, p = 0.41). Patients in the celecoxib arm used less prescription opioids (6.0 ± 3.6 v. 8.1 ± 4.0, p = 0.001) and stopped using oral opioids earlier (3.8 ± 2.6 days v. 5.7 ± 2.8 days, p < 0.001). No differences were seen in inpatient opioid or anti-emetic usage, perioperative complications, or days to return to ADLs. CONCLUSIONS: There was no difference in inpatient pain scores between patients who received celecoxib or ketorolac as part of multimodal pain control following robotic hysterectomy. Patients who received scheduled celecoxib for seven days after surgery used less prescription narcotics.
引用
- Ulm MA, ElNaggar AC, Tillmanns TD, et al. Celecoxib versus ketorolac following robotic hysterectomy for the management of postoperative pain: An open-label randomized control trial. Gynecol Oncol. 2018. PMID: 30121131. doi:10.1016/j.ygyno.2018.08.015
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。